Betamethasone Valerate
Betamethasone
Ointments
Administration, Topical
Glucocorticoids
Psoriasis
Pancreatic Juice
New Zealand
Health Personnel
Attitude of Health Personnel
Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. (1/23)
OBJECTIVE: To determine whether a three day burst of a potent corticosteroid is more effective than a mild preparation used for seven days in children with mild or moderate atopic eczema. DESIGN: Randomised, double blind, parallel group study of 18 weeks' duration. SETTING: 13 general practices and a teaching hospital in the Nottingham area. PARTICIPANTS: 174 children with mild or moderate atopic eczema recruited from general practices and 33 from a hospital outpatient clinic. INTERVENTIONS: 0.1% betamethasone valerate applied for three days followed by the base ointment for four days versus 1% hydrocortisone applied for seven days. MAIN OUTCOME MEASURES: Primary outcomes were total number of scratch-free days and number of relapses. Secondary outcomes were median duration of relapses, number of undisturbed nights, disease severity (six area, six sign atopic dermatitis severity scale), scores on two quality of life measures (children's life quality index and dermatitis family impact questionnaire), and number of patients in whom treatment failed in each arm. RESULTS: No differences were found between the two groups. This was consistent for all outcomes. The median number of scratch-free days was 118.0 for the mild group and 117.5 for the potent group (difference 0.5, 95% confidence interval -2.0 to 4.0, P=0.53). The median number of relapses for both groups was 1.0. Both groups showed clinically important improvements in disease severity and quality of life compared with baseline. CONCLUSION: A short burst of a potent topical corticosteroid is just as effective as prolonged use of a milder preparation for controlling mild or moderate atopic eczema in children. (+info)Therapeutic effect of topical application of linoleic acid and lincomycin in combination with betamethasone valerate in melasma patients. (2/23)
Melasma is an acquired symmetric hypermelanosis characterized by irregular light-to gray-brown macules and patches on sun-exposed areas. Many therapeutic agents are available but are unsatisfactory. Recently, it has been demonstrated that lincomycin (LM) and linoleic acid (LA) can inhibit melanogenesis in vitro. Our purpose was to investigate the clinical efficacy of topical application of LM and LA in combination with betamethasone valerate (BV) in melasma patients. Forty-seven Korean female adults with clinically diagnosed melasma were enrolled in a 6-week, double-blind, randomized clinical trial. Patients were treated with one application of the vehicle (group A), 2% LM mixed with 0.05% BV (group B), or 2% LM mixed with 0.05% BV and 2% LA (group C) on the face every night. Determination of efficacy was based on the Melasma Area and Severity Index (MASI) score and objective assessment (no effect, mild, moderate, or excellent) at intervals of 2 weeks until the end of the study at 6 weeks. After 6 weeks, in comparison with the pre-treatment MASI score, the average MASI score of group C decreased to 68.9%, compared with 98% in group A (p<0.05) and 85.4% in group B. There was no statistically significant difference between group A and group B. Seven patients (43.7%) in group C revealed more than moderate improvement in objective assessment, compared with none in group A and two patients (12.5%) in group B. There were no significant side effects. Topical application of linoleic acid is considered to be effective in the treatment of melasma patients. (+info)The combined effect of topical CX-659S, a novel diaminouracil derivative, with topical corticosteroid on the three types of allergic responses in mice or guinea pigs. (3/23)
CX-659S ((S)-6-amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)-3-methyl-1-ph enyl-2,4(1H,3H)-pyrimidinedione), a newly discovered anti-inflammatory compound, exerts inhibitory effects against picryl chloride-, oxazolone-, and dinitrochlorobenzene-induced acute contact hypersensitivity responses (CHRs) characterized by Th1-type reactions. Furthermore, this compound suppressed chronic CHRs characterized by Th2-type reactions, which is well known to mimic many, if not all, events occurring within the lesional skin of patients with atopic dermatitis (AD). The present study was conducted to determine the combined effect of topical CX-659S with topical corticosteroid on immediate type (ITR), late type (LTR), and delayed type hypersensitivity (DTHR) allergic reactions that are involved in AD. An ineffective dose of CX-659S (0.03 mg/ear) combined with betamethasone valerate (BV) significantly potentiated inhibitory activity of BV alone (0.1 micro g/ear and 0.3Shizuokag/ear) on both the ITR and the LTR in mice with the ovalbumin (OVA)-induced biphasic cutaneous reaction. Furthermore, the combined effect of CX-659S with BV was also observed on dinitrochlorobenzene (DNCB)-induced DTHR in guinea pigs. These results indicate that CX-659S has a combined effect with corticosteroids on every ITR, LTR, and DTHR. Proper treatment with corticosteroids for a safe and effective treatment of AD is needed. Thus, the combination therapy of topical CX-659S with topical corticosteroid would be one of the potential approaches for devising a proper treatment with corticosteroids. (+info)Lichen sclerosus and acute urinary obstruction. (4/23)
A case of acute urinary obstruction due to early lichen sclerosus disease is described. In this case both histological corroboration and efficacy of potent topical steroid have been beneficial. (+info)Novel quantitative immunofluorescent technique reveals improvements in epidermal cell populations after mild treatment of psoriasis. (5/23)
A novel antibody labelling technique, the Zenon technique, was used in fluorescent immunohistochemistry for a better characterization of epidermal cell populations in a quantitative approach. With this technique, differences in proliferation and differentiation characteristics were shown between psoriatic and normal epidermis. The sensitivity of the method was investigated by assessing the effect of a mild topical treatment versus an emollient. Frozen sections of non-treated psoriatic epidermis and psoriatic epidermis treated once daily with either an emollient or betamethasone-17-valerate for only 2 weeks were compared immunohistochemically. Antibodies against keratin 6, 10 and 15 were labelled with the Zenon technique, whereas antibodies against the Ki-67 antigen and beta-1 integrin were covalently FITC-labelled. Using image analysis, these markers were measured in the epidermis in a standardized manner. Treatment of psoriasis with short-term topical steroid resulted towards normalization of Ki-67 antigen, beta-1 integrin, keratin 10 and keratin 6 expression, which are parameters for proliferation and differentiation. Although treatment with an emollient showed hardly any clinical response, changes towards a more normal phenotype could already be detected in several epidermal markers using this method. (+info)An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. (6/23)
To relieve the dryness of atopic dermatitis skin, a lipid formulation of fusidic acid and betamethasone 17-valerate (Fucicort Lipid cream) was developed as an additional treatment option to the established Fucicort cream. The two formulations were compared in patients with clinically infected atopic dermatitis. A total of 629 patients were randomized to twice daily double-blind treatment for 2 weeks with either Fucicort Lipid cream, Fucicort cream, or the new lipid cream vehicle. Clinical assessment was based on a Total Severity Score of the eczematous lesions. Bacteriological samples were taken at inclusion and at subsequent visit(s) if clinically infected lesions persisted. At the end of treatment, the mean reduction in Total Severity score was 82.9% in the lipid cream group, 82.7% in the cream group, and 33.0% in the vehicle group. The percentage of patients with a successful bacteriological response was 89.7%, 89.6% and 25.0%, respectively. Thus, the clinical and anti-bacterial effect of the lipid cream was found to be similar to that of the established cream formulation, and significantly better than that of the vehicle. The new lipid formulation, therefore, offers an efficient, safe and well-tolerated alternative for the short-term treatment of clinically infected atopic dermatitis. (+info)Possible involvement of 5-lipoxygenase metabolite in itch-associated response of mosquito allergy in mice. (7/23)
This study investigated endogenous mediators involved in mosquito allergy-associated itching in mice. An intradermal injection of an extract of mosquito salivary gland elicited marked scratching in sensitized mice. The 5-lipoxygenase inhibitor zileuton (100 mg/kg), the 5-lipoxygenase activating peptide inhibitor MK-886 (10 mg/kg), and the glucocorticoid betamethasone 17-valerate (3 mg/kg) inhibited the scratching. The scratching was not affected by the cyclooxygenase inhibitors indomethacin and ketoprofen, the TP prostanoid receptor antagonist SQ-29548, the leukotriene B(4) antagonist ONO-4057, the cysteinyl leukotriene antagonist pranlucast, the leukotriene D(4) antagonist MK-571, the platelet-activating factor antagonist CV-3988, the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester, the H(2) histamine-receptor antagonist cimetidine, the H(1) histamine-receptor antagonist terfenadine plus cimetidine, and cypoheptadine that blocks the 5-HT(1/2) serotonin receptors. Zileuton (100 mg/kg) inhibited the increased activity of the cutaneous nerve branch induced by an intradermal injection of the extract, suggesting the peripheral action. Zileuton and MK-886 (10 and 100 microM) did not affect high K(+)-induced increase in intracellular Ca(2+) concentration in cultured dorsal root ganglion neurons. The results suggest that 5-lipoxygenase metabolite(s) other than leukotriene B(4) and cysteinyl leukotrienes are involved in mosquito allergy-associated itching. (+info)The influence of sodium hyaluronate, L-leucine and sodium taurocholate on the nebulization of aqueous betamethasone-17-valerate suspensions. (8/23)
(+info)Psoriasis can affect any part of the body, including the scalp, elbows, knees, and lower back. The symptoms of psoriasis can vary in severity, and the condition can have a significant impact on quality of life. In addition to physical discomfort, psoriasis can also cause emotional distress and stigma.
There is no cure for psoriasis, but there are several treatment options available, including topical creams and ointments, light therapy, and systemic medications such as biologic drugs. With proper treatment, many people with psoriasis are able to manage their symptoms and improve their quality of life.
Psoriasis is relatively common, affecting approximately 2-3% of the global population, with a higher prevalence in Caucasians than in other races. It can occur at any age, but typically starts in the late teenage years or early adulthood. Psoriasis is often associated with other health conditions, such as diabetes, heart disease, and depression.
Overall, psoriasis is a complex and multifactorial condition that requires a comprehensive approach to management, including both physical and emotional support. With appropriate treatment and self-care, people with psoriasis can lead full and active lives.
Betamethasone valerate
Thermophobia
Schering-Plough
Fluocortolone
Domoprednate
Corticosteroid
Betamethasone dipropionate
Betamethasone
List of veterinary drugs
Topical glucocorticoids
Fusidic acid
List of GSK plc products
List of MeSH codes (D04)
Topical steroid
List of corticosteroid esters
Valeric acid
List of sex-hormonal aqueous suspensions
2014 Ju-Jitsu World Championships
Bolley Johnson
Don't Say No
Dewoitine D.371
Noor-ul-Ain
Benoist Land Tractor Type XII
Santa Cruz Barillas
Maria Margaret Pollen
Ronald Fogleman
Peachtree Street (song)
We, Too, Have a Job to Do
2021 Akkar explosion
Straubing Tigers
DailyMed - BETAMETHASONE VALERATE cream
MedlinePlus - Search Results for: betamethasone valerate
betamethasone valerate/PD - Search Results - PubMed
Betamethasone Valerate Cream - Uses, Side Effects & Warnings
Metabolism and degradation of betamethasone 17-valerate in homogenized living skin equivalent - PubMed
BETAMETHASONE VALERATE drug patent trials and PTAB cases for biologic and small molecule drugs
Betamethasone Valerate Topical
Betamethasone valerate 0.1% cream - Edinpharm
Betamethasone cream. Betamethasone valerate cream | Patient
Beta Scalp Application (Betamethasone Valerate) - 4NRX (UK)
Valerates - Betamethasone Valerate Cream Wholesale Trader from Nagpur
Fusibact B -fusidic acid 2% w/w Betamethasone(valerate) 0.1%& w/w - One Stop Pharmacy
Topical Corticosteroids: Overview
Books - NCBI
Biomarkers Search
JDH Pharmaceutical products
Licorice - Health Information Library | PeaceHealth
COVID-19: 2 More Mucosal Skin Ulcer Cases Reported in Male Teens
Daubnet Community • Grobock, Berek, Silas and Emet Kenya
The treatment of psoriasis in primary care - BPJ 23 September 2009
Teva Products & Contact Information | MIMS Hongkong
Biomarkers Search
MeSH Browser
Otomax Otic Ointment for Dogs Rx - PBS Animal Health
Ointment10
- Betamethasone Valerate Cream, Ointment and Lotion contain betamethasone valerate USP, a synthetic adrenocorticosteroid for dermatologic use. (nih.gov)
- Each gram of the 0.1% Ointment contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in an ointment base of white petrolatum and mineral oil. (nih.gov)
- The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment. (nih.gov)
- 12. [Topical treatment of dermatoses with difluocortolone valerate fatty ointment]. (nih.gov)
- In addition, the patients received betamethasone valerate 0.1% ointment once daily, hydrocortisone 2.5 mg buccal tablets 4 times daily, analgesia with acetaminophen and ibuprofen, and IV hydration. (medscape.com)
- The patient received betamethasone valerate 0.1% ointment for the lips and penis, intraoral dexamethasone solution, viscous lidocaine, acetaminophen, and ibuprofen. (medscape.com)
- 2. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. (nih.gov)
- 4. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. (nih.gov)
- 10. Calcipotriol-betamethasone ointment versus calcipotriol ointment in the treatment of psoriasis vulgaris. (nih.gov)
- 16. Low incidence of hypercalcemia following combined calcipotriol hydrate/betamethasone dipropionate ointment treatment in Japanese patients with severe psoriasis vulgaris. (nih.gov)
Metabolism of betamethasone 17-valerate2
Topical corticosteroids1
- This review identifies that topical corticosteroids of high (betamethasone-17-valerate) and medium potency (mometasone furoate 0.1%), as well as barrier films such as Mepitel®, Mepilex Lite®, and Hydrofilm®, are effective in managing acute breast radiodermatitis. (bvsalud.org)
Corticosteroids1
- D07AC01 - betamethasone : Belongs to the class of potent (group III) corticosteroids. (mims.com)
Lotion3
- Each gram of the 0.1% Lotion contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in a vehicle of isopropyl alcohol and water slightly thickened with carbomer 934P. (nih.gov)
- Can Drug Store has provided information from third parties intended to increase awareness and does not contain all the information about Ectosone Lotion -Generic (Betamethasone Valerate Lotion). (candrugstore.com)
- Talk to your doctor or a qualified medical practitioner for medical attention, advice, or if you have any concerns about Ectosone Lotion -Generic (Betamethasone Valerate Lotion). (candrugstore.com)
Scalp application8
- What is Beta Scalp Application (Betamethasone Valerate) used for? (4nrx-uk.md)
- Beta Scalp Application (Betamethasone Valerate) is a topical corticosteroid prescribed to treat seborrhoeic dermatitis or psoriasis affecting the scalp. (4nrx-uk.md)
- How should I use Beta Scalp Application (Betamethasone Valerate)? (4nrx-uk.md)
- Beta Scalp Application (Betamethasone Valerate) should be used according to the instructions provided by your doctor and printed on the packaging to ensure the safest and most effective results from treatment. (4nrx-uk.md)
- What are the side effects of Beta Scalp Application (Betamethasone Valerate)? (4nrx-uk.md)
- Beta Scalp Application (Betamethasone Valerate) should not be applied to skin that is broken or severely damaged. (4nrx-uk.md)
- Strictly use Beta Scalp Application (Betamethasone Valerate) as prescribed and follow all instructions provided by your doctor. (4nrx-uk.md)
- Beta Scalp Application (Betamethasone Valerate) may not be safe or suitable for all patients. (4nrx-uk.md)
Gentamicin1
- Otomax contains gentamicin sulfate, betamethasone valerate and clotrimazole in a mineral oil-based system containing a plasticized hydrocarbon gel. (pbsanimalhealth.com)
Ectosone1
- Ectosone cream (betamethasone Valerate) is a topical corticosteroid used for the topical treatment of skin irritations. (doctorsolve.com)
Formulation2
- 9. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. (nih.gov)
- 14. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. (nih.gov)
Clotrimazole1
- There are also betamethasone preparations available which contain an antibacterial agent (such as clioquinol, neomycin or fusidic acid), or an antifungal agent (such as clotrimazole). (patient.info)
Efficacy3
- 3. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. (nih.gov)
- 5. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. (nih.gov)
- 12. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. (nih.gov)
Dermatoses1
- Betamethasone Valerate Topical is used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and other conditions. (tabletwise.net)
Pharmaceuticals1
- Betamethasone-21 is intended for Pharmaceuticals applications. (alsachim.com)
Treatment7
- Betamethasone valerate in the treatment of summer hay fever. (nih.gov)
- Short courses of betamethasone may also be prescribed for the treatment of psoriasis for small areas such as the scalp, soles of the feet, or palms of the hands. (patient.info)
- 1. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. (nih.gov)
- 7. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. (nih.gov)
- 8. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. (nih.gov)
- 11. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. (nih.gov)
- 15. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. (nih.gov)
Potent1
- Betamethasone is classed as a potent topical corticosteroid . (patient.info)
Side Effects3
- The following is a list of possible side-effects that may occur in medicines that contain Betamethasone Valerate Topical . (tabletwise.net)
- Betamethasone Valerate Topical may also cause side-effects not listed here. (tabletwise.net)
- If you experience drowsiness , dizziness, hypotension or a headache as side-effects when using Betamethasone Valerate Topical medicine then it may not be safe to drive a vehicle or operate heavy machinery. (tabletwise.net)
Suitable1
- Betamethasone is not generally suitable for children, although short courses of up to two weeks may occasionally be prescribed for a child by a skin specialist doctor. (patient.info)
Skin3
- Degradation profiles (%) of betamethasone 17-valerate remaining in the culture medium with skin homogenate did not differ from those without homogenate. (nih.gov)
- However, the conversion of betamethasone 21-valerate to betamethasone was accelerated by skin homogenate, indicating that LSE has a sufficient level of esterase. (nih.gov)
- VALERATE N CREAM is a combination medicine that is used to treat various types of skin infections. (globalstarinternational.in)
High3
- Betamethasone, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. (nih.gov)
- Betamethasone 17-valerate, betamethasone 21-valerate and betamethasone were measured by a normal-phase high-performance liquid chromatographic (HPLC) method. (nih.gov)
- betamethasone valerate If a high yield of form II. (mainraum-gruenderhaus.de)
Symptoms1
- Betamethasone relieves the symptoms of a flare-up by reducing inflammation, itching and redness. (patient.info)
Product1
- Our product range includes a wide range of betamethasone valerate cream. (globalstarinternational.in)
Doctor2
- Before using Betamethasone Valerate Topical , inform your doctor about your current list of medications, over the counter products (e.g. vitamins, herbal supplements, etc.), allergies, pre-existing diseases, and current health conditions (e.g. pregnancy, upcoming surgery, etc. (tabletwise.net)
- Your doctor will tell you how often to apply betamethasone. (patient.info)
Safe2
- Is Betamethasone Valerate Topical safe to use when pregnant? (tabletwise.net)
- Is Betamethasone Valerate Topical safe while breastfeeding? (tabletwise.net)
Dipropionate1
- 4. Acrodermatitis continua of Hallopeau on toes successfully treated with a two-compound product containing calcipotriol and betamethasone dipropionate. (nih.gov)
Topical1
- 16. Using oral tetracycline and topical betamethasone valerate to treat acrodermatitis continua of hallopeau. (nih.gov)
Activity1
- Betamethasone, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. (nih.gov)